Navigation Links
AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
Date:5/25/2010

REDWOOD CITY, Calif., May 25 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of the ARX-02 Sufentanil NanoTab™ Breakthrough Pain Management System in the treatment of cancer breakthrough pain in opioid-tolerant patients. The primary endpoint of time-weighted Sum of the Pain Intensity Difference over the first 30 minutes after dosing (SPID-30) was highly statistically significant for ARX-02 compared to placebo (p < 0.001). Richard King, AcelRx President and Chief Executive Officer, commented, "AcelRx has now successfully completed Phase 2 studies with all three sufentanil-based development programs in progress at the company. These programs, targeting post-operative patient-controlled analgesia (ARX-01), outpatient procedural sedation (ARX-03) and now cancer breakthrough pain (ARX-02) represent important advances to meet significant unmet medical needs in these patient populations."

The initial open-label titration phase of the study enrolled 42 cancer patients with breakthrough pain. Of those patients, 36 (86%) were successful in titrating to an effective dose of ARX-02 with minimal side effects. In the double-blind, placebo-controlled phase of the study, titrated patients were randomized to receive a blinded sequence of seven doses of ARX-02 and three doses of placebo for use in treating ten distinct breakthrough pain events over the course of a three-week period. Patients recorded their pain intensity and pain relief scores for 60 minutes following administration of study drug or placebo using an electronic diary.

In addition to ARX-02 achieving statistical superiority over placebo on the SPID-30 primary endpoint, key secondary endpoints demonstrate that ARX-02 achieves rapid onset of analg
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
2. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
5. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
6. ProUroCare Medical Announces Filing of Request to Classify the Prostate Mechanical Imager ("PMI") as a Class II Device
7. Applied Precision Announces New Products for Life Sciences Microscopy at the 110th American Society for Microbiology Meeting in San Diego, CA, May 23-26th.
8. Hisamitsu Pharmaceutical Announces Two New FDA Approved Over-The-Counter Pain Relief Patches
9. Fred A. Baughman Jr., MD Announces: Vets Deaths Are Not Suicides or Overdoses but Sudden Cardiac Deaths Due to Prescription Antipsychotics and Antidepressants
10. Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010
11. Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Mo., Feb. 14, 2011 K-V Pharmaceutical Company (NYSE: ... into a definitive agreement with a group of institutional ... from a private placement of 9,950,000 shares of its ... Company will use $20 million of the proceeds from ...
... commonly prescribed osteoporosis drug is associated with a slightly ... osteonecrosis of the jaw; nonetheless the risk remains extremely ... Journal of Dental Research, the official journal of ... the findings are provocative, study authors say they should ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 2K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 3K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 4K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 5K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 6K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 7K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 8K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 9K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 10K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 11K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 12K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 13Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 2Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 3Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 4
(Date:7/10/2014)... News) -- Adults with dyslexia are more likely to ... teenagers than people who don,t have the learning disorder, ... affects up to 10 percent of people, causes problems ... of adults with this condition said they suffered physical ... those without dyslexia. "Even after accounting for age, ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... may help ease the hot flashes that often accompany menopause, ... more than 50 percent of menopausal women, said Dr. Taraneh ... science at the Icahn School of Medicine at Mount Sinai ... experience more than 10 hot flashes a day, and she ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... the Twitter wars that break out regularly between outspoken celebrities ... for your own relationship, a new study suggests. High ... couple, even if the couple is in a long-term relationship, ... users. In turn, that friction can lead to cheating ...
(Date:7/10/2014)... that the "Mississippi Baby," believed to have been functionally ... detectable levels of the virus, the Elizabeth Glaser Pediatric ... remains hopeful that the scientific breakthrough that allowed the ... two years will continue to help researchers understand how ... , "Although we had high hopes that the child ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
Breaking Medicine News(10 mins):Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... OXFORD, England, July 13 International medical,communications ... the Year at the Communique Awards in London ... by an independent panel of,communications experts, who assess ... for healthcare clients, along with business strategy,client retention, ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a ... scheduled a conference call and web cast on Thursday, July 30, 2009, ... ended June 28, 2009. Gentiva plans to issue its financial news release ... , The conference call is open to investment analysts ...
... July 13 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for the treatment ... has received a $1.5 million milestone payment from Biogen ... of a Raf kinase inhibitor development candidate for the ...
... New data pooled from four large, "real world" ... VIII (rFVIII-FS) reduced bleeding and provided data regarding ... mild-to-severe hemophilia A. Additionally, rates of inhibitor formation ... untreated patients. The data were presented at the ...
... , SUNNYVALE, Calif., July 13 Cepheid (Nasdaq: CPHD ... & Drug Administration (FDA) to market its Xpert(R) C. difficile ... of the bacterium that causes Clostridium difficile infection (CDI). ... for CDI to deliver both rapid turnaround and a high degree ...
... , PORT WASHINGTON, N.Y., July 13 ... of the American Medical Association has granted a CPT Category ... (TM) (MCG) system. MCG is the World,s first Internet based, ... for interactive online diagnosis. The MCG is intended as ...
Cached Medicine News:Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 2Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 3Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 4Health News:Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 3Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 4Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 5Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 2Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 3Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 4Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 5Health News:AMA Grants New Category III CPT Code to Premier Heart's Multifunction CardioGram(TM) (MCG) 2
... provided by a cool-running, energy efficient LEDs ... you need to see without affecting the ... they are maintenance free so you'll never ... Phoroptor comes with a limited lifetime warranty, ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
10 (mm) smooth platform; Serrated handle in stainless steel....
Compatible with the Volcano Therapeutics Trak Back II Disposable Catheter Pullback Device,and the Volcano Therapeutics In-Vision Imaging System....
Medicine Products: